BRPI0921802A2 - combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor - Google Patents

combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor

Info

Publication number: BRPI0921802A2
Authority: BR; Brazil
Prior art keywords: inhibitor; pi3k; phosphatidylinositol; kinase; combination
Prior art date: 2008-10-31

Application number

BRPI0921802A

Other languages

English (en)

Inventor

Carlos Garcia-Echeverria

Sauveur-Michel Maira

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-31

Filing date

2009-10-29

Publication date

2016-09-27

2009-10-29 Application filed by Novartis Ag filed Critical Novartis Ag

2016-09-27 Publication of BRPI0921802A2 publication Critical patent/BRPI0921802A2/pt

2018-03-13 Publication of BRPI0921802A8 publication Critical patent/BRPI0921802A8/pt

Links

229940124302 mTOR inhibitor Drugs 0.000 title 1
239000003628 mammalian target of rapamycin inhibitor Substances 0.000 title 1
229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Virology (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI0921802A 2008-10-31 2009-10-29 uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo. BRPI0921802A8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08168044		2008-10-31
PCT/EP2009/064274 WO2010049481A1 (en)	2008-10-31	2009-10-29	Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

Publications (2)

Publication Number	Publication Date
BRPI0921802A2 true BRPI0921802A2 (pt)	2016-09-27
BRPI0921802A8 BRPI0921802A8 (pt)	2018-03-13

Family

ID=40332588

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0921802A BRPI0921802A8 (pt)	2008-10-31	2009-10-29	uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo.

Country Status (12)

Country	Link
US (3)	US20110195966A1 (pt)
EP (1)	EP2349275B1 (pt)
JP (4)	JP2012506898A (pt)
KR (1)	KR20110090911A (pt)
CN (2)	CN102202668A (pt)
AU (1)	AU2009309616B2 (pt)
BR (1)	BRPI0921802A8 (pt)
CA (1)	CA2736361C (pt)
ES (1)	ES2627677T3 (pt)
MX (1)	MX2011004585A (pt)
RU (2)	RU2538683C2 (pt)
WO (1)	WO2010049481A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100048524A1 (en)	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US8476282B2 (en) *	2008-11-03	2013-07-02	Intellikine Llc	Benzoxazole kinase inhibitors and methods of use
PT2365802T (pt)	2008-11-11	2017-11-14	Univ Texas	Microcápsulas de rapamicina e utilização para o tratamento de cancro
WO2010091306A1 (en)	2009-02-05	2010-08-12	Tokai Pharmaceuticals	Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
GB2478556A (en) *	2010-03-09	2011-09-14	Myrovlytis Technology Ventures Ltd	A composition for use in the treatment of Birt-Hogg-Dubô sydrome
EP2675450B1 (en) *	2011-02-16	2016-02-10	Novartis AG	Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
JP6130305B2 (ja)	2011-02-23	2017-05-17	インテリカイン，エルエルシー	キナーゼ阻害剤の組み合わせおよびそれらの使用
US9127074B2 (en) *	2011-03-07	2015-09-08	Fondazione Telethon	TFEB variants and uses thereof
US20140066474A1 (en) *	2011-04-25	2014-03-06	Novartis Ag	Combination of phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
ES2618489T3 (es)	2011-05-04	2017-06-21	Intellikine, Llc	Composiciones farmacéuticas combinadas y usos de las mismas
AU2012313888B2 (en)	2011-09-27	2016-03-31	Novartis Ag	3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
CN106924741A (zh) *	2011-11-08	2017-07-07	因特利凯有限责任公司	使用多种药剂的治疗方案
US20130209543A1 (en) *	2011-11-23	2013-08-15	Intellikine Llc	Enhanced treatment regimens using mtor inhibitors
UY34632A (es) *	2012-02-24	2013-05-31	Novartis Ag	Compuestos de oxazolidin- 2- ona y usos de los mismos
RU2012112128A (ru) *	2012-03-29	2013-10-10	Холин Максим Николаевич	ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ
US9296733B2 (en)	2012-11-12	2016-03-29	Novartis Ag	Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
WO2014160328A1 (en)	2013-03-13	2014-10-02	The Board Of Regents Of The University Of Texas System	Mtor inhibitors for prevention of intestinal polyp growth
EP2968370A4 (en)	2013-03-14	2016-09-21	Univ Maryland	AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF
KR20150131224A (ko)	2013-03-14	2015-11-24	노파르티스 아게	돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
RU2015143437A (ru)	2013-03-15	2017-04-27	Дженентек, Инк.	Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака
PE20161063A1 (es)	2013-05-01	2016-10-22	Hoffmann La Roche	Compuestos de biheteroarilo y usos de los mismos
EP3033088A4 (en)	2013-08-12	2017-03-08	Tokai Pharmaceuticals, Inc.	Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
CN103483345B (zh) *	2013-09-25	2016-07-06	中山大学	Pi3k激酶抑制剂、包含其的药物组合物及其应用
AU2014373683B2 (en)	2013-12-31	2020-05-07	Rapamycin Holdings, Llc	Oral rapamycin nanoparticle preparations and use
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
WO2016168658A1 (en)	2015-04-15	2016-10-20	University Of Massachusetts	Compositions and methods for xi chromosome reactivation
EP3297629A1 (en)	2015-05-20	2018-03-28	Novartis AG	Pharmaceutical combination of everolimus with dactolisib
BR112019010470A2 (pt)	2016-11-23	2019-09-10	Novartis Ag	métodos de realce de resposta imune com everolimo, dactolisib ou ambos
US10596165B2 (en)	2018-02-12	2020-03-24	resTORbio, Inc.	Combination therapies
KR20210158019A (ko)	2020-06-23	2021-12-30	주식회사 온코빅스	포스파티딜이노시톨 3-키나제(pi3k) 억제제로써 pten 과오종 증후군에 의한 종양 세포의 성장 또는 증식을 억제하는데 유용한 신규한 피리미딘 유도체 및 이의 약제학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 약제학적 조성물
CN112294967A (zh) *	2020-09-30	2021-02-02	四川大学	一种mTOR抑制剂与抗癌药物的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL153474A0 (en) *	2000-06-26	2003-07-06	Stressgen Biotechnologies Corp	Human papilloma virus treatment
CN101039952A (zh) *	2004-10-13	2007-09-19	惠氏公司	作为pi3k抑制剂的17－羟基渥曼青霉素类似物
WO2007010012A2 (en) *	2005-07-20	2007-01-25	Novartis Ag	Combination of a pyrimidylaminobenzamide and an mtor kinase inhibitor
KR101464384B1 (ko) *	2005-11-22	2014-11-21	쿠도스 파마슈티칼스 리미티드	ｍＴＯＲ 억제제로서 피리도피리미딘, 피라조피리미딘 및피리미도피리미딘 유도체
JO2660B1 (en) *	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
US7659274B2 (en) *	2006-01-25	2010-02-09	Osi Pharmaceuticals, Inc.	Unsaturated mTOR inhibitors
WO2007120897A2 (en) *	2006-04-13	2007-10-25	The Trustees Of Columbia University In The City Of New York	Compositions and intraluminal devices for inhibiting vascular stenosis
AU2008213808B2 (en) *	2007-02-06	2011-11-10	Novartis Ag	PI 3-kinase inhibitors and methods of their use
RU2478387C2 (ru) *	2007-02-20	2013-04-10	Новартис Аг	ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR
CN101896177A (zh) *	2007-12-13	2010-11-24	诺瓦提斯公司	用于治疗癌症的治疗剂的组合

2009
- 2009-10-29 RU RU2011121508/15A patent/RU2538683C2/ru not_active IP Right Cessation
- 2009-10-29 KR KR1020117009771A patent/KR20110090911A/ko not_active Ceased
- 2009-10-29 ES ES09744391.5T patent/ES2627677T3/es active Active
- 2009-10-29 MX MX2011004585A patent/MX2011004585A/es active IP Right Grant
- 2009-10-29 EP EP09744391.5A patent/EP2349275B1/en not_active Not-in-force
- 2009-10-29 WO PCT/EP2009/064274 patent/WO2010049481A1/en not_active Ceased
- 2009-10-29 CA CA2736361A patent/CA2736361C/en not_active Expired - Fee Related
- 2009-10-29 CN CN2009801431736A patent/CN102202668A/zh active Pending
- 2009-10-29 CN CN201510402018.9A patent/CN105030784A/zh active Pending
- 2009-10-29 BR BRPI0921802A patent/BRPI0921802A8/pt not_active IP Right Cessation
- 2009-10-29 JP JP2011533721A patent/JP2012506898A/ja not_active Withdrawn
- 2009-10-29 AU AU2009309616A patent/AU2009309616B2/en not_active Ceased
- 2009-10-29 US US13/123,956 patent/US20110195966A1/en not_active Abandoned
2014
- 2014-04-15 RU RU2014115188/15A patent/RU2014115188A/ru not_active Application Discontinuation
- 2014-09-05 JP JP2014181069A patent/JP2015013883A/ja not_active Withdrawn
2015
- 2015-11-24 US US14/950,869 patent/US20160136175A1/en not_active Abandoned
2016
- 2016-07-06 JP JP2016134514A patent/JP2017002058A/ja not_active Ceased
2018
- 2018-01-16 US US15/872,043 patent/US20180133226A1/en not_active Abandoned
- 2018-07-20 JP JP2018136756A patent/JP2018197243A/ja active Pending

Also Published As

Publication number	Publication date
JP2017002058A (ja)	2017-01-05
CN102202668A (zh)	2011-09-28
RU2014115188A (ru)	2015-10-20
JP2018197243A (ja)	2018-12-13
WO2010049481A1 (en)	2010-05-06
CN105030784A (zh)	2015-11-11
US20180133226A1 (en)	2018-05-17
EP2349275A1 (en)	2011-08-03
JP2012506898A (ja)	2012-03-22
JP2015013883A (ja)	2015-01-22
AU2009309616A1 (en)	2010-05-06
RU2011121508A (ru)	2012-12-10
ES2627677T3 (es)	2017-07-31
AU2009309616B2 (en)	2014-02-13
RU2538683C2 (ru)	2015-01-10
AU2009309616A2 (en)	2011-07-07
CA2736361C (en)	2017-10-10
BRPI0921802A8 (pt)	2018-03-13
US20160136175A1 (en)	2016-05-19
EP2349275B1 (en)	2017-03-08
KR20110090911A (ko)	2011-08-10
CA2736361A1 (en)	2010-05-06
US20110195966A1 (en)	2011-08-11
MX2011004585A (es)	2011-06-01

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-04-24	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2020-11-10	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 11A ANUIDADE.
2021-03-02	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2601 DE 10-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
IL280173A (en)	2021-03-01	Inhibitors of brutons tyrosine kinase
BRPI0921156A2 (pt)	2016-02-23	inibidores de pi3k/mtor quinase
BRPI0910346A2 (pt)	2015-10-06	compostos de benzopirano e benzoxapina inibidores de pi3k e métodos de uso
HUS1900029I1 (hu)	2020-04-28	Kináz inhibitor foszforszármazékok
CY2017012I1 (el)	2017-11-14	Αναστολεις κινασης τυροσινης bruton
CR10369A (es)	2009-01-09	Pyrimidine derivatives as pi3k inhibitors
BRPI0915231A2 (pt)	2018-06-12	compostos inibidores de quinase e métodos de uso
DK2848610T3 (da)	2017-11-06	Hæmmere af kinaseaktivitet
BRPI0716781A2 (pt)	2014-11-18	Inibidores da quinase
BRPI1011129A2 (pt)	2016-11-01	métodos e compostos inibidores de janus cinase
BRPI0912294A2 (pt)	2015-10-20	compostos de triazina como inibidores de pi3 quinase e de mtor
NO20084665L (no)	2009-01-06	Quinazoliner for PDK1-inhibering
NO20084533L (no)	2009-01-09	Pyrimidin-derivat som PI3K-inhibitor og bruk av dette
DK2277509T3 (da)	2015-04-13	DPP IV inhibitorformuleringer
EP2040546A4 (en)	2009-12-23	tyrosine kinase inhibitor
BR112012008483A2 (pt)	2019-09-24	combunações de um inibidor de pi3k e um inibidor de mex
BRPI0717928A2 (pt)	2013-11-05	Imidazopiridazinas como inibidores da cinase de lipídio pi3k
EP2038272A4 (en)	2011-01-05	PYRIDINONYL-PDK1 INHIBITORS
SMP200800022B (it)	2008-04-02	Benzimidazoli sostituiti come inibitori delle chinasi
DK2402317T3 (da)	2013-10-07	DGAT-inhibitor
DK1986650T3 (da)	2012-08-13	Manipulationssikre doserignsformer
ATE506358T1 (de)	2011-05-15	2-benzylpyridazinonderivate als met-kinasehemmer
BRPI0922880A2 (pt)	2018-07-24	compostos inibidores de quinase
BRPI0907931A2 (pt)	2015-07-28	Derivado de pirrolopirimidina como inibidor de pi3k e uso do mesmo
DOP2007000082A (es)	2007-12-31	Inhibidores de quinasas de puntos de control